Vaccine & Boosters

Before you pick a time: 

  • Please ensure we have accurate email and cell phone contact information, so that we may reach you in a timely manner if necessary.
  • If you are currently participating in or have participated in a COVID vaccine study, please contact your study coordinator before scheduling.
  • Those 5+ who are moderately or severely immunocompromised should get an additional primary shot of Pfizer-BioNTech COVID-19 vaccine. Immunosuppressed patients 12+ qualify for a total of 4 doses (3 primary doses, followed by 1 booster dose 3 months later). Contact your primary care provider with questions or to schedule a vaccine appointment.

Approval has now been granted for the administration of "mix and match" vaccines--a booster different from the vaccine originally administered. If you are interested in pursuing this option, please call (832) 632-6731 or email C19Vacsch@utmb.edu for assistance.

BEGIN THE SCHEDULING PROCESS BELOW:

Select desired dose of the COVID-19 Vaccine:

   

  • Patient is 18 years or older. (Pfizer/Moderna)

    Please Note: Multiple vaccine sites may be listed. Scroll down to ensure that you have selected a site convenient to you.

    VT 1265

    If you need assistance determining if an individual meets the criteria outlined by the CDC and Texas Department of State Health Services to schedule a COVID-19 vaccine, or if you have any COVID-19 vaccine questions, please call (832) 632-6731 or email C19Vacsch@utmb.edu.

  • Please review dosing, timing and age guidelines for the general population and for immunocompromised individuals to determine if/when the patient qualifies for a second dose.

    • Patient is 18 years or older. Select which vaccine the patient would you like to receive:

        

      • Please Note: Multiple vaccine sites may be listed. Scroll down to ensure that you have selected a site convenient to you.

        VT 1266

      • Please Note: Multiple vaccine sites may be listed. Scroll down to ensure that you have selected a site convenient to you.

        VT 1267

      If you need assistance determining if an individual meets the criteria outlined by the CDC and Texas Department of State Health Services to schedule a COVID-19 vaccine, or if you have any COVID-19 vaccine questions, please call (832) 632-6731 or email C19Vacsch@utmb.edu.

  • Please review dosing, timing and age guidelines for the general population and for immunocompromised individuals to determine if/when the patient qualifies for a second dose.

    • Patient is 18 years or older. Select which vaccine the patient would you like to receive:

        

      • Please Note: Multiple vaccine sites may be listed. Scroll down to ensure that you have selected a site convenient to you.

        VT 1293

      • Please Note: Multiple vaccine sites may be listed. Scroll down to ensure that you have selected a site convenient to you.

        VT 1295

      If you need assistance determining if an individual meets the criteria outlined by the CDC and Texas Department of State Health Services to schedule a COVID-19 vaccine, or if you have any COVID-19 vaccine questions, please call (832) 632-6731 or email C19Vacsch@utmb.edu.

Reporting an Adverse Vaccine Event

To ensure safety, there’s a significant effort to track possible side effects and adverse events from the COVID-19 vaccines. Use these links if you experience anything concerning or unexpected with the vaccine.

Report your event that required medical attention to UTMB (UTMB Employees Only)
Report your event to HHS (Vaccine Adverse Event Reporting System-VAERS)
Use the V-Safe Tool (app from the CDC)

COVID-19 Testing

UTMB is offering expedited COVID-19 testing for our workforce through MyChart (click to log in). Details on how to schedule an employee COVID test using MyChart are below for both current MyChart users and employees new to MyChart (must be on UTMB network to view instructions).
What do my COVID-19 test results mean?

UTMB Safety Requirements

NEW Top Buttons

Masking
Sick or Exposed
Travel Information
Visitation Policy

Latest Updates

  • COVID-19 Clinical Task Force: Revised COVID-19 precautions take effect on Sept. 29, 2022

    As a result of the high levels of vaccine- and infection-induced immunity and the availability of effective treatments and prevention tools, along with the local alert designation of GREEN (low COVID risk) per the CDC data tracker, new revised COVID-19 recommendations will be in effect beginning Sept. 29. The changes are detailed in this latest message from the COVID-19 Task Force. This message is intended for UTMB employees, who must be logged onto the UTMB network to access the full text. Thank you.

  • Sept. 6, 2022: COVID-19 Clinical Task Force updates visitation, social distancing and masking requirements

    Due to the declining rates of COVID-19 infections in our region, modifications have been made to the UTMB social distancing and masking requirements and visitation policy, effective September 7, 2022. The changes are detailed in this latest message from the COVID-19 Task Force. This message is intended for UTMB employees, who must be logged onto the UTMB network to access the full text. Thank you.

  • COVID-19 update on the current wave, test-to-treat program and new vaccination option

    The UTMB COVID-19 Clinical Task Force shared updates on high test positivity rates among patients tested at UTMB, information on the successful COVID-19 test-to-treat program, and the new Novavax vaccine, an effective option for those reluctant or unable to get mRNA vaccines.

  • Vaccines available for children ages 6 months to 5 years

    Many parents, caregivers and clinicians have been waiting for a COVID-19 vaccine for younger children. Now that the CDC has approved the vaccine for children ages 6 months to 5 years, UTMB will begin offering the vaccine at our pediatric clinics beginning Monday, June 27.

  • June 23, 2022: Changes in testing policies for procedures, hospital admissions

    During the past few weeks, we have noted a rapid increase in COVID-19 test positivity in our community—now at 30%—and a gradually increasing inpatient census. As a result of these recent developments, changes in COVID-19 testing policies are being made...

Find Past Updates >>